Fig. 1From: Clinical utility of tumor genomic profiling in patients with high plasma circulating tumor DNA burden or metabolically active tumorsStudy schema. This study included 125 consecutive patients with locally advanced or metastatic solid tumors who underwent FoundationACT testing between November 17, 2015, and April 17, 2017. Among 90 patients with available FoundationACT reports, 81 patients had no interval treatment and 18F-FDG PET/CT scans performed at our institution within 45Â days of blood sampling for imaging quantification analyses. The concordance rate of GA detection between 51 matched FoundationACT and FoundationOne cases was calculated and further analyzed for NCCN-recommended molecular targets in 42 patientsBack to article page